Session Time: 4:30pm-6:00pm
Presentation Time: 5:06pm-5:18pm
Location: Room 311
*Purpose: Mixed hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis than pure HCC tumors however only a few series describing outcomes following liver transplantation (LT) have been reported. We sought to compare post-OLT outcomes of HCC-CCA and HCC in the largest series from the Western hemisphere to date.
*Methods: This is a single-center retrospective cohort study of all consecutive patients with HCC treated with between 1998 and 2018. Patient and tumor characteristics as well as post-LT survival and oncologic outcomes were compared among patients with pure HCC and those with mixed HCC-CCA identified on liver explant.
*Results: A total of 18 HCC-CCA cases were identified and their outcomes compared to 615 pure HCC patients. The median follow-up duration for the cohort was 54 months (IQR 23-103). Both groups were comparable in terms of preoperative findings such as baseline, laboratory and radiological variables. Notable differences however were seen on liver explant pathology, HCC-CCA tumors were significantly more aggressive: 41% were Grade 3 and 41% Grade 4 vs 28 and 16% (p=0.033) of HCC tumors; 60% exhibited microvascular (vs 26%, p=0.006) and 36% lymphatic invasion (vs 5%, p<0.001). Patients with mixed HCC-CCA tumors had a significantly lower 5-year survival rate of 39 vs 75% (p<0.001) as well as a lower 5-year recurrence-free survival rate of 42 vs 87% (p<0.001). Moreover, the time to recurrence was significantly shorter for HCC-CCA patients with a median of 7 (IQR 3 - 8) vs 15 months (IQR 8 - 33) (p=0.004).
*Conclusions: These findings from the largest Western series to date further confirm that mixed HCC-CCA are more aggressive than pure HCC tumors and confer a worse prognosis following liver transplantation.
To cite this abstract in AMA style:Najjar M, Bruestle K, Jiang P, Robbins-Juarez S, Hwang R, Mathur A, Verna EC, Griesemer A, Samstein B, Kato T, Saenger YM, Halazun KJ, Emond JC. Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcioma [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-liver-transplantation-for-mixed-hepatocellular-cholangiocarcioma/. Accessed November 29, 2020.
« Back to 2019 American Transplant Congress